{"url_path":"/sec/vor/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1817229/0001193125-26-220689-index.html","accession_number":"0001193125-26-220689","cik":"0001817229","ticker":"VOR","issuer_name":"Vor Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817229/0001193125-26-220689-index.html","primary_entity_key":"0001817229","primary_entity_name":"Vor Biopharma Inc."},"word_count":49,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDirector and Officer Trading Arrangements\n\n64\n\n \n\nDuring the quarter ended March 31, 2026, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a \"Rule 10b5-1 trading arrangement\" or a \"non-Rule 10b5-1 trading arrangement,\" each as defined in Regulation S-K Item 408.\n\n \n\n65"}